Women have played a crucial role in rare disease awareness and better care, overcoming gender biases and systemic challenges ...

Diversity and inclusion are critical to business success, particularly when fostering innovation and creativity. At Mednet, ...

Eli Lilly has announced that it is investing $4.5bn into a new US facility for advanced manufacturing and drug development. The Lilly Medicine Foundry will give the company the ability to research new ...

Sanofi and Regeneron’s Dupixent (dupilumab) has been approved by the US Food and Drug Administration (FDA) as an add-on maintenance treatment for chronic obstructive pulmonary disease (COPD). The ...

Research on the state of the customer experience (CX) that the global pharmaceutical industry provides to healthcare professionals (HCPs) has been released by DT Consulting, an Indegene company. For ...

As part of PCOS Awareness Month, Dr Tayyibah Ali takes a look at the ways employers can help support colleagues with chronic conditions like PCOS ...

NHS England has announced that hundreds of babies have begun to be tested for over 200 genetic conditions as part of a study led by Genomics England. The Generation Study is evaluating the potential ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved Pharming Group’s Joenja (leniolisib) to treat patients with the rare immune disease activated phosphoinositide 3-kinase ...

During a recent media audit on sickle cell disease, an intriguing pattern emerged that the name ‘Christopher’ was the third most mentioned term. This unexpected finding resonated with me, as I share ...

Like most people these days, I have been experimenting with various artificial intelligence (AI) tools this past year. It’s remarkable to see the progress made in the technology compared to only a few ...

Risk taking is complicated. In business, ebullient entrepreneurs are lauded for putting their livelihood on the line and taking risks, while serial gamblers who do the same are frowned upon. When it ...

The US Food and Drug Administration (FDA) has granted rare paediatric disease (RPD) designation to Enterprise Therapeutics’ investigational cystic fibrosis therapy. Estimated to affect more than ...